#oncology — Public Fediverse posts

Lixte Biotech advances precision oncology with LB-100, a first-in-class therapy designed to enhance cancer treatment effectiveness. Strategic partnerships and expanded clinical trials mark significant momentum. #Oncology #Biotech

LIXTE Biotechnology accelerates cancer innovation with Liora Technologies acquisition, advancing LB-100 across clinical programs. #Oncology #Biotech

Lixte Biotech advances LB-100, a first-in-class therapy to enhance cancer treatment effectiveness while reducing toxicity. New strategic partnerships and expanded clinical trials mark growing momentum in precision oncology. #Oncology #Biotech

LIXTE Biotechnology reports 40% disease control rate in ovarian cancer trial combining LB-100 with dostarlimab, supporting expansion of patient enrollment. #Biotech #Oncology

Kairos Pharma honored at 2026 Pinnacle Awards for innovative cancer drug resistance solutions. Lead candidate ENV-105 targets CD105 to enhance therapy effectiveness across multiple cancer indications. #Biotech #Oncology

Oncotelic Therapeutics reports FY 2025 net income of $249M, driven by $365.4M non-cash gain from GMP Bio joint venture valuation. Clinical-stage biotech advancing oncology pipeline. #Biotech #Oncology

The MYC protein, conventionally known for accelerating cancer growth, also actively repairs dangerous DNA breaks in tumor cells, allowing them to survive therapies designed to destroy them.
#Oncology #Genetics #CellBiology #sflorg
https://www.sflorg.com/2026/05/ongy05152601.html

Oncology is shifting toward combination therapies. First-in-class PP2A inhibitor LB-100 enhances existing treatments to overcome resistance, advancing multi-drug strategies in cancer care. #Oncology #Biotech

Oncology is shifting toward combination therapies. First-in-class PP2A inhibitor LB-100 enhances existing treatments to overcome resistance, advancing multi-drug strategies in cancer care. #Oncology #Biotech

Oncology is shifting toward combination therapies. First-in-class PP2A inhibitor LB-100 enhances existing treatments to overcome resistance, advancing multi-drug strategies in cancer care. #Oncology #Biotech

Oncology is shifting toward combination therapies. First-in-class PP2A inhibitor LB-100 enhances existing treatments to overcome resistance, advancing multi-drug strategies in cancer care. #Oncology #Biotech

Oncology is shifting toward combination therapies. First-in-class PP2A inhibitor LB-100 enhances existing treatments to overcome resistance, advancing multi-drug strategies in cancer care. #Oncology #Biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. Clinical trials underway for multiple solid tumors. #Oncology #Biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. Clinical trials underway for multiple solid tumors. #Oncology #Biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. Clinical trials underway for multiple solid tumors. #Oncology #Biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. Clinical trials underway for multiple solid tumors. #Oncology #Biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. Clinical trials underway for multiple solid tumors. #Oncology #Biotech

Lantern Pharma schedules FDA Type C meeting for HARMONIC trial amendments evaluating LP-300 in lung cancer, with data showing 8.3-month median PFS in EGFR-mutant patients. #Oncology #Biotech

Lantern Pharma schedules FDA Type C meeting for HARMONIC trial amendments evaluating LP-300 in lung cancer, with data showing 8.3-month median PFS in EGFR-mutant patients. #Oncology #Biotech

Lantern Pharma schedules FDA Type C meeting for HARMONIC trial amendments evaluating LP-300 in lung cancer, with data showing 8.3-month median PFS in EGFR-mutant patients. #Oncology #Biotech

Lantern Pharma schedules FDA Type C meeting for HARMONIC trial amendments evaluating LP-300 in lung cancer, with data showing 8.3-month median PFS in EGFR-mutant patients. #Oncology #Biotech

Lantern Pharma schedules FDA Type C meeting for HARMONIC trial amendments evaluating LP-300 in lung cancer, with data showing 8.3-month median PFS in EGFR-mutant patients. #Oncology #Biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. #Oncology #Biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. #Oncology #Biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. #Oncology #Biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. #Oncology #Biotech

Molecular testing is revolutionizing CNS cancer diagnosis, enabling more accurate tumor identification and personalized treatment strategies for patients. #Biotech #Oncology

Oncotelic Therapeutics highlighted for strategic asset valuation approach, leveraging its diversified pipeline and $1B+ valued stake in GMP Bio. #Biotech #Oncology

Tonix Pharmaceuticals presents preclinical immuno-oncology data at AACR 2026, highlighting TNX-1700 and TNX-4700 as promising cancer immunotherapy candidates. #Biotech #Oncology

Oncotelic Therapeutics featured in BioMedWire editorial on how advancing drug pipelines and AI-driven oncology innovation are reshaping biotech valuations as measurable financial assets. #Biotech #Oncology

Oncotelic Therapeutics advances oncology pipeline through strategic partnerships and AI innovation, with joint venture contributing $249M balance sheet increase. #Biotech #Oncology

Oncotelic Therapeutics featured in analysis on how late-stage drug pipelines drive real-time valuation in biotech. The company's oncology-focused assets and strategic partnerships position it for value creation. #Biotech #Oncology

LIXTE Biotechnology advances precision oncology with LB-100, a novel compound designed to enhance chemotherapy and radiation while reducing side effects. Clinical trials underway. #Oncology #Biotech

GeoVax advances Gedeptin, a gene therapy designed to sensitize cold tumors to checkpoint inhibitors. Preclinical data shows synergistic effects, with Phase 2 trials planned in head and neck cancer. #Oncology #Biotech

TransCode Therapeutics appoints Dr. Anna Moore as Scientific Advisory Board Chair and partners with Michigan State University to advance its RNA-based cancer pipeline, including lead candidate TTX-MC138. #Oncology #Biotech

LIXTE Biotechnology advances precision cancer care with LB-100, designed to enhance chemotherapy and radiation while reducing side effects. Clinical trials underway. #Oncology #Biotech

GeoVax advances Gedeptin toward Phase 2 initiation in 2027, evaluating the oncology candidate in combination with checkpoint inhibitors for head and neck cancer. Strategic partnerships in focus. #Biotech #Oncology

Lantern Pharma advances withZeta.ai with ZetaSwarm multi-agent AI and ZetaOmics analytics tools, expanding AI-driven drug discovery capabilities. #Oncology #AI

Lantern Pharma to report Q1 2026 results May 15, featuring clinical trial updates and launch of withZeta.ai, a commercial AI platform for drug development. #Oncology #AI

OS Therapies advances OST-HER2 toward global approval for osteosarcoma. EMA rolling review initiated, regulatory endpoints aligned, and dense 2026 catalyst calendar set. #Biotech #Oncology

Lantern Pharma secures $4.4M via registered direct offering and plans to spin off its withZeta.ai AI platform as independent entity. #Biotech #Oncology

Kairos Pharma CEO to present at LD Micro Invitational XVI on May 18, showcasing ENV-105 clinical progress in oncology therapeutics. #Biotech #Oncology

Oncotelic Therapeutics doses first patient in Phase 1b trial of Sapu003, a novel IV everolimus formulation targeting advanced mTOR-sensitive tumors. The weekly IV approach aims to overcome limitations of oral delivery. #Oncology #Biotech

“Totally Unexpected” – Scientists Discover Pancreatic Cancer’s Fatal Addiction

A new study found that pancreatic cancer cells depend on inflammation triggered by damaged mitochondria and the TLR3/TRAF6…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Science #cancer #cellbiology #inflammation #Oncology #Tumor
https://www.newsbeep.com/us/641282/

“Totally Unexpected” – Scientists Discover Pancreatic Cancer’s Fatal Addiction

A new study found that pancreatic cancer cells depend on inflammation triggered by damaged mitochondria and the TLR3/TRAF6…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Science #cancer #cellbiology #inflammation #Oncology #Tumor
https://www.newsbeep.com/us/641282/

Soligenix advances groundbreaking solutions for Cutaneous T-Cell Lymphoma, targeting early detection and innovative treatment strategies for this challenging rare disease #MedicalResearch #Oncology

Soligenix advances groundbreaking solutions for Cutaneous T-Cell Lymphoma, targeting early detection and innovative treatment strategies for this challenging rare disease #MedicalResearch #Oncology

Soligenix advances groundbreaking solutions for Cutaneous T-Cell Lymphoma, targeting early detection and innovative treatment strategies for this challenging rare disease #MedicalResearch #Oncology

Soligenix advances groundbreaking solutions for Cutaneous T-Cell Lymphoma, targeting early detection and innovative treatment strategies for this challenging rare disease #MedicalResearch #Oncology

Soligenix advances groundbreaking solutions for Cutaneous T-Cell Lymphoma, targeting early detection and innovative treatment strategies for this challenging rare disease #MedicalResearch #Oncology